Advertisement
Advertisement
U.S. markets close in 3 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Satellos Bioscience Inc. (MSCLF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.2747-0.0599 (-17.89%)
As of 09:33AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.3345
Open0.2747
BidN/A x N/A
AskN/A x N/A
Day's Range0.2747 - 0.2747
52 Week Range0.0250 - 1.0000
Volume3,500
Avg. Volume5,442
Market Cap11.48M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MSCLF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SATELLOS BIOSCIENCE INC
    Technical Assessment: Bearish in the Intermediate-TermThe stock market soared on Tuesday, so it's not surprising that Wednesday was flat -- but we certainly had a lot of good intermarket news. Yields fell across the curve, crude oil and some grain and soft commodity prices got hammered, and the U.S. Dollar Index fell slightly. If you are bullish on stocks, you can't ask for much more than that.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Newsfile

    Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million

    Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the "Offering") of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satell

  • Newsfile

    Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit

    Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging

  • Newsfile

    Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million

    Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos proposes to raise gross proceeds of u

Advertisement
Advertisement